189 related articles for article (PubMed ID: 17650216)
1. Histopathology of breast carcinoma following neoadjuvant systemic therapy: a common association between letrozole therapy and central scarring.
Thomas JS; Julian HS; Green RV; Cameron DA; Dixon MJ
Histopathology; 2007 Aug; 51(2):219-26. PubMed ID: 17650216
[TBL] [Abstract][Full Text] [Related]
2. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer.
Baselga J; Semiglazov V; van Dam P; Manikhas A; Bellet M; Mayordomo J; Campone M; Kubista E; Greil R; Bianchi G; Steinseifer J; Molloy B; Tokaji E; Gardner H; Phillips P; Stumm M; Lane HA; Dixon JM; Jonat W; Rugo HS
J Clin Oncol; 2009 Jun; 27(16):2630-7. PubMed ID: 19380449
[TBL] [Abstract][Full Text] [Related]
3. Gene expression profiles differentiating between breast cancers clinically responsive or resistant to letrozole.
Miller WR; Larionov A; Renshaw L; Anderson TJ; Walker JR; Krause A; Sing T; Evans DB; Dixon JM
J Clin Oncol; 2009 Mar; 27(9):1382-7. PubMed ID: 19224856
[TBL] [Abstract][Full Text] [Related]
4. Estrogen-independent proliferation is present in estrogen-receptor HER2-positive primary breast cancer after neoadjuvant letrozole.
Ellis MJ; Tao Y; Young O; White S; Proia AD; Murray J; Renshaw L; Faratian D; Thomas J; Dowsett M; Krause A; Evans DB; Miller WR; Dixon JM
J Clin Oncol; 2006 Jul; 24(19):3019-25. PubMed ID: 16754938
[TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant endocrine therapy for postmenopausal patients with hormone receptor-positive early breast cancer: a new concept.
Iwata H
Breast Cancer; 2011 Apr; 18(2):92-7. PubMed ID: 21140250
[TBL] [Abstract][Full Text] [Related]
6. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
Ellis MJ; Tao Y; Luo J; A'Hern R; Evans DB; Bhatnagar AS; Chaudri Ross HA; von Kameke A; Miller WR; Smith I; Eiermann W; Dowsett M
J Natl Cancer Inst; 2008 Oct; 100(19):1380-8. PubMed ID: 18812550
[TBL] [Abstract][Full Text] [Related]
7. Review of the development of letrozole and its use in advanced breast cancer and in the neoadjuvant setting.
Bhatnagar AS
Breast; 2006 Feb; 15 Suppl 1():S3-13. PubMed ID: 16500235
[TBL] [Abstract][Full Text] [Related]
8. Estrogen receptors evolution in neoadjuvant aromatase inhibitor (AI) therapy for breast cancer in elderly women: stability of hormonal receptor expression during treatment.
Salmon RJ; Alran S; Malka I; de Cremoux P; Rosty C; Languille O; Campana F; ; Sigal-Zafrani B
Am J Clin Oncol; 2006 Aug; 29(4):385-8. PubMed ID: 16891867
[TBL] [Abstract][Full Text] [Related]
9. Invasive lobular carcinoma: response to neoadjuvant letrozole therapy.
Dixon JM; Renshaw L; Dixon J; Thomas J
Breast Cancer Res Treat; 2011 Dec; 130(3):871-7. PubMed ID: 21870129
[TBL] [Abstract][Full Text] [Related]
10. An ER activity profile including ER, PR, Bcl-2 and IGF-IR may have potential as selection criterion for letrozole or tamoxifen treatment of patients with advanced breast cancer.
Henriksen KL; Rasmussen BB; Lykkesfeldt AE; Møller S; Ejlertsen B; Mouridsen HT
Acta Oncol; 2009; 48(4):522-31. PubMed ID: 19173092
[TBL] [Abstract][Full Text] [Related]
11. Future directions in the treatment of hormone-sensitive advanced breast cancer: the RAD001 (Everolimus)-letrozole clinical program.
Lane HA; Lebwohl D
Semin Oncol; 2006 Apr; 33(2 Suppl 7):S18-25. PubMed ID: 16730273
[TBL] [Abstract][Full Text] [Related]
12. Randomized phase II trial of letrozole and letrozole plus low-dose metronomic oral cyclophosphamide as primary systemic treatment in elderly breast cancer patients.
Bottini A; Generali D; Brizzi MP; Fox SB; Bersiga A; Bonardi S; Allevi G; Aguggini S; Bodini G; Milani M; Dionisio R; Bernardi C; Montruccoli A; Bruzzi P; Harris AL; Dogliotti L; Berruti A
J Clin Oncol; 2006 Aug; 24(22):3623-8. PubMed ID: 16877730
[TBL] [Abstract][Full Text] [Related]
13. Understanding the BIG results: Insights from the BIG 1-98 trial analyses.
Wardley AM
Adv Ther; 2008 Dec; 25(12):1257-75. PubMed ID: 19096768
[TBL] [Abstract][Full Text] [Related]
14. Letrozole is superior to anastrozole in suppressing breast cancer tissue and plasma estrogen levels.
Geisler J; Helle H; Ekse D; Duong NK; Evans DB; Nordbø Y; Aas T; Lønning PE
Clin Cancer Res; 2008 Oct; 14(19):6330-5. PubMed ID: 18829517
[TBL] [Abstract][Full Text] [Related]
15. Down-regulation of phosphatidylinositol 3'-kinase/AKT/molecular target of rapamycin metabolic pathway by primary letrozole-based therapy in human breast cancer.
Generali D; Fox SB; Brizzi MP; Allevi G; Bonardi S; Aguggini S; Milani M; Bersiga A; Campo L; Dionisio R; Vergoni F; Giardini R; Dogliotti L; Bottini A; Harris AL; Berruti A
Clin Cancer Res; 2008 May; 14(9):2673-80. PubMed ID: 18451231
[TBL] [Abstract][Full Text] [Related]
16. Low residual proliferation after short-term letrozole therapy is an early predictive marker of response in high proliferative ER-positive breast cancer.
Bedard PL; Singhal SK; Ignatiadis M; Bradbury I; Haibe-Kains B; Desmedt C; Loi S; Evans DB; Michiels S; Dixon JM; Miller WR; Piccart MJ; Sotiriou C
Endocr Relat Cancer; 2011 Dec; 18(6):721-30. PubMed ID: 21984694
[TBL] [Abstract][Full Text] [Related]
17. Antitumour and biological effects of letrozole and GnRH analogue as primary therapy in premenopausal women with ER and PgR positive locally advanced operable breast cancer.
Torrisi R; Bagnardi V; Pruneri G; Ghisini R; Bottiglieri L; Magni E; Veronesi P; D'Alessandro C; Luini A; Dellapasqua S; Viale G; Goldhirsch A; Colleoni M
Br J Cancer; 2007 Sep; 97(6):802-8. PubMed ID: 17712311
[TBL] [Abstract][Full Text] [Related]
18. Maintenance hormone therapy with letrozole after first-line chemotherapy for advanced breast cancer.
Bertelli G; Garrone O; Bertolotti L; Occelli M; Conforti S; Marzano N; Febbraro A; Carlini P; Liossi C; Del Mastro L; Leonard RC
Oncology; 2005; 68(4-6):364-70. PubMed ID: 16020964
[TBL] [Abstract][Full Text] [Related]
19. Increase in response rate by prolonged treatment with neoadjuvant letrozole.
Dixon JM; Renshaw L; Macaskill EJ; Young O; Murray J; Cameron D; Kerr GR; Evans DB; Miller WR
Breast Cancer Res Treat; 2009 Jan; 113(1):145-51. PubMed ID: 18264759
[TBL] [Abstract][Full Text] [Related]
20. Letrozole suppresses plasma estradiol and estrone sulphate more completely than anastrozole in postmenopausal women with breast cancer.
Dixon JM; Renshaw L; Young O; Murray J; Macaskill EJ; McHugh M; Folkerd E; Cameron DA; A'Hern RP; Dowsett M
J Clin Oncol; 2008 Apr; 26(10):1671-6. PubMed ID: 18375896
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
